Patients with advanced stage prostate cancer are commonly treated with Androgen deprivation therapy (ADT). However, about 80% of patients who receive this therapy say that before and after treatment they experience hot flashes. To address this limitation, researchers at the Moffitt Cancer Center are working to understand genetic factors and other characteristics that might make patients with prostate cancer more prone to experience hot flashes during and after ADT.
The majority of treatments for cancer cause undesirable adverse events, some so debilitating that patients opt to discontinue the treatment, even with the risk of disease progression or recurrence. Evidence has shown that about 25% of patients with prostate cancer report experiencing hot flashes with ADT. In this new study, the research team aimed to understand which patients were more prone to experience these symptoms in order to help clinicians with treatment decisions.
They assessed a total of 60 patients with prostate cancer who were receiving tr